{"ticker": {"uuid": "614077ab-88bb-482e-a85f-d131644972a8", "symbol": "IDYA", "name": "Ideaya Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ideaya Biosciences chief accounting officer sells $382,130 in stock", "summary": "Andres Ruiz Briseno, Chief Accounting Officer of IDEAYA Biosciences, sold 9,550 shares of the company's stock for approximately $382,130. The sale was carried out under a Rule 10b5-1 trading plan and occurred after an exercise of stock options. Despite the sale, the company maint", "url": "https://www.investing.com/news/insider-trading-news/ideaya-biosciences-chief-accounting-officer-sells-382130-in-stock-93CH-4784996", "source_name": "Investing.com", "published_at": "2026-07-10T04:41:21", "published_display": "10 Jul 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Ideaya Biosciences Inc For: 9 July By Investing.com", "summary": "This article reports on a Form 4 filing for Ideaya Biosciences Inc. dated July 9, 2026. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The content provided is minimal, simply stating the company, the form type, and the date.", "url": "https://ng.investing.com/news/stock-market-news/form-4-ideaya-biosciences-inc-for-9-july-93CH-2593972", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T04:39:11", "published_display": "10 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences chief accounting officer sells $382,130 in stock By Investing.com", "summary": "Ideaya Biosciences' Chief Accounting Officer, Andres Ruiz Briseno, sold 9,550 shares totaling $382,130 on July 7, 2026, under a Rule 10b5-1 trading plan. This transaction occurred after he acquired the same number of shares through stock option exercise. Despite the sale occurrin", "url": "https://ng.investing.com/news/stock-market-news/ideaya-biosciences-chief-accounting-officer-sells-382130-in-stock-93CH-2593956", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T22:02:06", "published_display": "09 Jul 2026 22:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences Insider Sold Shares Worth $382,131, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ideaya-biosciences-insider-sold-shares-210147696.html", "source_name": "MT Newswires", "published_at": "2026-07-09T21:01:47+00:00", "published_display": "09 Jul 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares", "summary": "IDEAYA Biosciences' Chief Accounting Officer, Andres Ruiz Briseno, exercised 9,550 stock options at $12.86 per share and subsequently sold all 9,550 common shares at a weighted average price of $40.01 per share. This transaction was pre-planned under a Rule 10b5-1 trading plan ad", "url": "https://www.stocktitan.net/sec-filings/IDYA/form-4-ideaya-biosciences-inc-insider-trading-activity-e43d0f0b0f21.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:10:06", "published_display": "09 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary", "summary": "IDEAYA Biosciences (IDYA) presented a summary of its 43rd Annual J.P. Morgan Healthcare Conference, highlighting multiple first-in-class programs and key clinical milestones. The company is advancing six programs in the clinic and targeting three new INDs for 2025, with significa", "url": "https://quartr.com/events/ideaya-biosciences-idya-43rd-annual-j-p-morgan-healthcare-conference-2025_FkPPo41h", "source_name": "Quartr", "published_at": "2026-07-09T04:39:11", "published_display": "09 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary", "summary": "IDEAYA Biosciences (IDYA) provided an update at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, highlighting the rapid enrollment in its Darovasertib trial for metastatic uveal melanoma, with potential for accelerated approval data readout by late next year. The com", "url": "https://quartr.com/events/ideaya-biosciences-inc-idya-7th-annual-evercore-isi-healthconx-healthcare-conference_FkPPoGuL", "source_name": "Quartr", "published_at": "2026-07-09T04:39:11", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) RBC Capital Markets Global Healthcare Conference 2025 summary", "summary": "IDEAYA Biosciences anticipates a transformational year with four major data readouts for Darovasertib in uveal melanoma, including randomized PFS and OS data by year-end 2025, and plans to launch a registrational neoadjuvant study. The company aims for Accelerated Approval for Da", "url": "https://quartr.com/events/ideaya-biosciences-inc-idya-rbc-capital-markets-global-healthcare-conference-2025_FkPPoZcN", "source_name": "Quartr", "published_at": "2026-07-08T16:40:10", "published_display": "08 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences highlights its precision oncology pipeline as Nasdaq-listed cancer drug developer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQNjhQSnNSVnpQWHVTRVVaQnl4OV8tTTZCVUJ4NG5LeTIzTDBGZEZWeloyWUZEd3d3ZFNTZnhsNWhrVDIwNGlMcEpZal9VLU5ZUS1xcENxanZQZGRnaTFUMEVUTXV6aGhMQ3hHd2EwY3QyUEFMOXhMOUk3M2RNazZWaXZ4cVEtQ0tqM3VFQUUwb2J0VDJBaTJxdkJUei1pVE1PMjF3c01FbEk0Ung4ZHNOSnhpUUZBakJMWFhHdjEyZ3E?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-08T13:40:27+00:00", "published_display": "08 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) Joins Russell Growth Benchmarks, Is The Stock Fully Priced?", "summary": "IDEAYA Biosciences (IDYA) has been included in several Russell Growth Benchmarks, leading to increased investor interest and a 30-day stock return of 43.2%. While the company's Price-to-Sales (P/S) ratio of 17.1x appears high compared to industry averages and its estimated fair P", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/ideaya-biosciences-idya-joins-russell-growth-benchmarks-is-t", "source_name": "Simply Wall Street", "published_at": "2026-07-08T04:11:13", "published_display": "08 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] IDEAYA Biosciences, Inc. SEC Filing", "summary": "This article details an SEC Form 144 filing by IDEAYA Biosciences, Inc. (IDYA) concerning a proposed sale of securities. The document outlines the filer and issuer information, securities to be sold including common stock acquired through stock option exercise, and specifies J.P.", "url": "https://www.stocktitan.net/sec-filings/IDYA/144-ideaya-biosciences-inc-sec-filing-8c8a28ff56c5.html", "source_name": "Stock Titan", "published_at": "2026-07-08T04:09:33", "published_display": "08 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Ideaya Biosciences Inc. (IDYA) Affects Rotational Strategy Timing", "summary": "Ideaya Biosciences Inc. (IDYA) shows strong sentiment across all horizons, leading to an overweight bias. AI models have generated three trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and stop-loss levels. The analysis indica", "url": "https://news.stocktradersdaily.com/news_release/20/How_Ideaya_Biosciences_Inc._IDYA_Affects_Rotational_Strategy_Timing_070826025401_1783493641.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T03:10:36", "published_display": "08 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63", "summary": "Truist Financial has reiterated its Buy rating for IDEAYA Biosciences (IDYA.US) and set a target price of $63. This indicates a positive outlook from the firm regarding the biotechnology company's stock performance.", "url": "https://www.moomoo.com/news/post/72590618/truist-financial-maintains-ideaya-biosciences-idyaus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-07T19:09:33", "published_display": "07 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts IDEAYA Biosciences Price Target to $48 From $53, Maintains Outperform Rating", "summary": "RBC Capital has adjusted its price target for IDEAYA Biosciences to $48, down from $53, while reiterating an \"Outperform\" rating on the stock. This revision reflects a change in valuation despite the maintained positive outlook for the company's performance.", "url": "https://www.moomoo.com/news/post/72585854/rbc-capital-adjusts-ideaya-biosciences-price-target-to-48-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T16:39:38", "published_display": "07 Jul 2026 16:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences stock hits 52-week high at $39.28 By Investing.com", "summary": "Ideaya Biosciences Inc. (NASDAQ: IDYA) has reached a new 52-week high of $39.28, representing an 85.02% increase over the past year and bringing its market capitalization to $3.73 billion. Analysts have set a high price target of $66, reflecting strong investor confidence. The co", "url": "https://za.investing.com/news/stock-market-news/ideaya-biosciences-stock-hits-52week-high-at-3928-93CH-4356737", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T15:40:26", "published_display": "06 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences stock hits 52-week high at $39.28", "summary": "Ideaya Biosciences Inc. stock has reached a 52-week high of $39.28, reflecting an 85.02% increase over the past year and a market capitalization of $3.73 billion. This surge follows a successful public offering raising $345 million and the initiation of a Phase 1 clinical trial f", "url": "https://m.uk.investing.com/news/stock-market-news/ideaya-biosciences-stock-hits-52week-high-at-3928-93CH-4757904?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-06T15:39:27", "published_display": "06 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion", "summary": "IDEAYA Biosciences (IDYA) has been added to several Russell growth and small-cap indexes, increasing its visibility to institutional investors. This inclusion, however, does not alter the core investment risk that depends on successful clinical and regulatory outcomes for its onc", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/how-investors-are-reacting-to-ideaya-biosciences-idya-broad", "source_name": "Simply Wall Street", "published_at": "2026-07-03T14:39:15", "published_display": "03 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "IDEAYA Biosciences announced it granted non-qualified stock options for 98,000 shares to four new employees on June 25, 2026. These grants, made under the 2023 Employment Inducement Incentive Award Plan, are a material inducement for their employment, in compliance with Nasdaq Li", "url": "https://finance.yahoo.com/healthcare/articles/ideaya-biosciences-announces-inducement-grants-100000351.html", "source_name": "Market source", "published_at": "2026-06-30T18:10:29", "published_display": "30 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark", "summary": "IDEAYA Biosciences, Inc. (NasdaqGS:IDYA) has been added to the Russell 2500 Growth Benchmark. The company, an oncology firm focused on developing therapies for cancer, saw its stock price increase by 1.97%. IDEAYA Biosciences engages in the discovery, development, and commerciali", "url": "https://www.marketscreener.com/news/ideaya-biosciences-inc-nasdaqgs-idya-added-to-russell-2500-growth-benchmark-ce7f5fdfdd89f726", "source_name": "marketscreener.com", "published_at": "2026-06-30T13:11:14", "published_display": "30 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. \u2013 FWB:30J", "summary": "This article provides financial information for IDEAYA Biosciences, Inc. (FWB:30J) on TradingView, specifically focusing on its enterprise value to EBIT forward. It lists various general financial and community features available on the platform for this company's stock.", "url": "https://www.tradingview.com/symbols/FWB-30J/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:09:39", "published_display": "30 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark", "summary": "IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), a company focused on oncology therapies, has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion highlights the company's growth trajectory and its position within the small-cap market. The article also provides an o", "url": "https://www.marketscreener.com/news/ideaya-biosciences-inc-nasdaqgs-idya-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f525", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:40:07", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark", "summary": "IDEAYA Biosciences, Inc. (NasdaqGS:IDYA) has been added to the Russell 3000E Growth Benchmark. This news, published on June 29, 2026, highlights the company's inclusion in a significant stock market index. IDEAYA Biosciences is a precision oncology company focused on developing t", "url": "https://www.marketscreener.com/news/ideaya-biosciences-inc-nasdaqgs-idya-added-to-russell-3000e-growth-benchmark-ce7f5fdedc80ff26", "source_name": "marketscreener.com", "published_at": "2026-06-29T13:11:14", "published_display": "29 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of IDEAYA Biosciences, Inc. \u2013 FWB:30J", "summary": "The article provides the \"Price to sales forward\" data for IDEAYA Biosciences, Inc. (FWB:30J) as listed on the Frankfurt Stock Exchange. It indicates that the market is closed and no trades have occurred for this specific financial metric. The data is available through TradingVie", "url": "https://www.tradingview.com/symbols/FWB-30J/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:41:08", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of IDEAYA Biosciences, Inc. \u2013 NASDAQ:IDYA", "summary": "This article provides financial data for IDEAYA Biosciences, Inc. (IDYA) focusing on its price to book forward ratio. It highlights the company's listing on the Nasdaq Stock Market under the Pharmaceuticals: Major category within Health Technology. The content also includes vario", "url": "https://www.tradingview.com/symbols/NASDAQ-IDYA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:41:08", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark", "summary": "IDEAYA Biosciences, Inc. (NasdaqGS: IDYA) has been added to the Russell 2000 Growth Benchmark. The company, which specializes in oncology therapies, recently announced its CEO as Chairman of the Board and initiated a Phase 1/2 clinical study for pancreatic and lung cancers. This ", "url": "https://www.marketscreener.com/news/ideaya-biosciences-inc-nasdaqgs-idya-added-to-russell-2000-growth-benchmark-ce7f5fdede81f02c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:17", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. \u2013 NASDAQ:IDYA", "summary": "This article provides a brief mention of the \"Enterprise value to EBIT forward\" metric for IDEAYA Biosciences, Inc. (NASDAQ: IDYA). It appears to be a stub or a section within a larger financial data platform like TradingView, designed to display key financial ratios for the comp", "url": "https://www.tradingview.com/symbols/NASDAQ-IDYA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:40:17", "published_display": "29 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of IDEAYA Biosciences, Inc. \u2013 NASDAQ:IDYA", "summary": "This article focuses on the enterprise value to revenue forward metric for IDEAYA Biosciences, Inc. (NASDAQ: IDYA). The content presented is a financial data point from TradingView, indicating a key valuation multiple for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-IDYA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:39:07", "published_display": "29 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of IDEAYA Biosciences, Inc. \u2013 FWB:30J", "summary": "The article provides a financial metric for IDEAYA Biosciences, Inc. (FWB:30J), specifically its enterprise value to revenue forward. It notes that this data was \"Made by humans\" and that the market was closed with no trades at the time of publication. The content appears to be a", "url": "https://www.tradingview.com/symbols/FWB-30J/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:40:17", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of IDEAYA Biosciences, Inc. \u2013 FWB:30J", "summary": "This article focuses on the \"Price to book forward\" financial metric for IDEAYA Biosciences, Inc. (FWB:30J) on the Frankfurt Stock Exchange. It indicates no trades and a closed market at the time of publication. The page appears to be a financial data portal displaying an overvie", "url": "https://www.tradingview.com/symbols/FWB-30J/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T22:10:18", "published_display": "28 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) First Patient Enrollment Puts Valuation Back In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences Elects CEO Yujiro Hata as Chairman", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ideaya-biosciences-elects-ceo-yujiro-105053830.html", "source_name": "MT Newswires", "published_at": "2026-06-17T10:50:53+00:00", "published_display": "17 Jun 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ideaya-biosciences-announces-yujiro-hata-100000788.html", "source_name": "PR Newswire", "published_at": "2026-06-17T10:00:00+00:00", "published_display": "17 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer research CEO Yujiro Hata now also chairs IDEAYA board", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPcm5DS1VrYnZZeE5RajNxc25nMDBpQV85MTFaOF9LRnJRd0t6OGZpWGFCeFdsQ3BjSnc3RkJFU215ZE9rcloxTktIbi1VaXE0azVGaXFpN0EtNnkzYV9pVHNXZWxkTjE2N1YxOEtlOGw0aVFMb0FSZi1SLTZjM2JxVDVqODlneHBwcDZRNDN0a2dBODMzc3Y0M0t2ZnhFeTBZRnFmVEJFZGRIZnR1SzU4WVRGVDVKWDdKNmlZT1p3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences' Phase 1 Clinical Trial of Lung, Pancreatic Cancer Treatment Enrolls First Patient", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ideaya-biosciences-apos-phase-1-115906264.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:59:06+00:00", "published_display": "15 Jun 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ideaya-biosciences-announces-ide892-potential-100000084.html", "source_name": "PR Newswire", "published_at": "2026-06-15T10:00:00+00:00", "published_display": "15 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ideaya-biosciences-idya-forms-clinical-102033649.html", "source_name": "Insider Monkey", "published_at": "2026-06-11T10:20:33+00:00", "published_display": "11 Jun 2026 10:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion H2 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZnRrTk5RMmEyY2ltNXVDUUVnWkUteXI2M2VqdEdiX2V1LXdhS1k0N3RzOWtLYXVqWXdMMzFoRTZuc1JXc3p3VEpXMm1BLUpBWlcydHZXbG0wY3d4Vjg0OHpXMzd5b2hUNEo4Q2thUjJfa1Q3SnpLaTlwRVFCaTk3ZndCQ2V1dzBjdlpoWVA5b2VsQ2ZmSWt5bTNPd3Q2bmY3TXdUdGZQVDJmTnJzb3NfcE9ybDdXX1paVWJ6T2pWYXRndw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences Closes $345 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ideaya-biosciences-closes-345-million-203152781.html", "source_name": "MT Newswires", "published_at": "2026-06-10T20:31:52+00:00", "published_display": "10 Jun 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (NASDAQ: IDYA) raises $323.6M via stock and pre-funded warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQWWhCSzE0Q3BKN2V3YURmMHQ0aUhLTG1JZU5oc2ZhR2pfTGlDMURydF9pSGthREZKNU14eWVhYlBuQmlNNk1xZU1MU0dldHVSTHJSV3lESXlhdkpuMGRKaWlTbG9FX1JFcnQ4TnRiMXItWVp1QW5scXlvcnQwakVlUXE5X1EyMjBCb0xJa01LVFYtTllNbE9ZbnRyNWNaZHZKZmh2WHNUVXd5eDlxMUxEOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNSUtydXJ1TUhMYlFiS0VEUFYxcWM2X0RLa1ZwUUhJZXNuR0x5TWRCeDlZVHNvMy1BU3VJd083QmZYU2ZCdzZnVU1femRpYXUwY19PeUdRNm9wRkQ5Qm5pZEoyN01fTktrOVREU1g3dEpVX2tqMGhhdHlEXzNGdEpLaDBiSkx3ZWNURnlxd3NnZkVSVHRSc1d6OU9KRWVvdTBwVVVLVVB6clpMRHJqMUs3VzIzZ2ZMdUszYVNKejlYMkpfa3NrS3dlNUJtXy11R1ExbzZtMEVVbnA1ejNDWTluMmI3LVZOWVVwbnVXSjE4NmhyVFZNaWVPN0oweENvOGZPY0JvN1A1NA?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOTGRNUGVqanZiVHpFNkJYWUllOGE2S2lCVFlZNEEtZnA4NzJZS1FHd2ZWOTJ3Z2E3R2VqNWJrTDdXR19UeGx6TVhHaXFieE41SldKWDJsdTV6QzZ3TTFtSnpqdHpJWHdpNHRDX2h2UE52QThSeEMtekE5Y0JJZUI1eGZkVTFpUzdiV1Q5YnV6SUFzWlFXVnN4YjBkc1VpbGFVd19HLWRMUlltXzYzODAtaFNfYV9kdmtmeTVnUDdB?oc=5", "source_name": "BioSpace", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA sets $27 price in $300M stock and warrant sale to investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeU5BaHEwdTc5eE1mZERMQUd0UXlOZDNnNXZPZHcwdVdySXlPRmUyTmNkSUx2YUJlTXBOLV9fWnZHd2FGY1NuaDNEeWxvamQ1VlFIMkdkY2Z2bWExZ2NjZDJKOENKd1haams2N0JYSS14TUcycEhzQjN4YTVYNUp2Zkdvd3NJMFE2Vzl1QW5fRHMyM1lSZHdoVWlOR2tySjByYzVmbDV4TW1LU1V3R1JKc0tlQjNFeW1hX21EWU5RWlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech IDEAYA grants new hires 221,000 options over 4 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOY2Vhb1pFcWtIMTRsa1FQLTBMb1I2Tk1kSWtZY0Q1YkV2LVV2bHRoNTgyc1hSZEcwZmNtVUJNQWRvR0laSEJwZDhsdWxiRVI3Ql9mLS0xUDJYRjU4cDVDN3NnLS0tRzlJbnRReHNQNUJ4aXdVVlZqRkRRR1U2VGtTazhHOEZGQ1hVVmE3SGtuMkNQR3Y5ZjQ2MG4tN1dYOG9SOVZmT3VPN1RzdjJnMzZXRnVLQktsa1RFUWhXMHVvcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IDEAYA Biosciences (IDYA) Persistent Losses Challenge Bullish High Revenue Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQdEhSYV9uUndPVmx1UVVaZ2k2b3ZrU28xemhMMXVyRDZZWlZ0U0IteGFEUElEazE0NXJPVDVJZlBHc01EdjZRS09zVjFXWnd3eGpGZk90ZXhGN2E3R0Jub01mSUtjT1N4cG00eUthYWtCYU1UMGRWVW9vLW56YnM4VW9Va2d2ZVNwZi1mdkZNQ29WdHNhWm92WGFsaXhlQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five new IDEAYA hires receive stock options at $29.10 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMzlrVnpnbld1bFJmNkFxY202LWppWTdBQktONW1VT09NZ1U4ZEFIS1VScjIwMHM2eWs4aXdRRldQZzhUdnktVEVuVERnSlJ0Vk1VM3Rfa1ZLOG14ZzRadVkyR215aFpkd0pSNWtnd0xfVmZXc2NqRlZKX01EMFdrMGg5Zjl4WFBmLWp1bGtDWnFUZTMtdUtIRU1nOS1ETzZ5d3dvb2M5RVhPZ2RPSk1rTVFWMnZrZHk0cnVlMEQ5aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ideaya Biosciences: Stock Buoyant On Good mUM Data - But Approval Not A Formality", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQRlYyTlZ0UUZvc1NrRUtIaG9xa0NQcEZjV00wZnBMWmU0QmtnZnlfd0xSeE9TZG5NUEZaSjhrS2MzQ0RCX0RhQ3AtQW5iTjhUMGtoSlNTcVYxT1JvemJiUUpFYjUzdXA3YnRmbld1ZHpMSG05X3ByYlFnQVctNm5yNUxoeXBJb0hza0xCcHNpcFpRSDV3X1JjY08xTS12X1hLTHl0NzVDbjBNQ3F2dHJwRlBDdVlWRGJtQWYw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQQ0d1eWtNUzI2MGV4amx0NkN0c0VGNjBWWURDRVM3dTJ5WS1kZjNqaUhyMXhqeFdQb2JfZFVoaXFFSEM4ZnZCQW16SnFFN0RwT1J0R2JNdG5sUEp2RFB1NlFGZDZUR3hudXA2emNTUVFJYlJsS1NycUhaQWVlX0FONmowZUV6Znd6TVBtN2t6Yk1ycndSUVNycUlkWVY2cnQ4?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA to reveal April 13 trial data in metastatic uveal melanoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxObGlRY1U2ckpQcGcyeXk5dVJGamhmS1ZEZWpMbXlvZkxWaFRVN0VienhqRXo1bGwyZHlmSHhOYmo2LTFLZTlXMzFSR2RWMUMza3FYX0h1dzdYNEw1M2hBSHF6akxsaDRlV0FYTk5hdjQtTWlXczhCdmxrNVRsamtjei1zazZOeTF3ZjQ5TEFCOEtycWZjUmp6RmlnS2s0NWtKZl9Ca0pETjEzT0xabFgta1RvRzFiYWFHdnc0QjV1WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQVjFwSldqWFJ6R1JFbFdXZy1XZjZVNmNSU1JKaVRCcGswcUVWdGdiUktRd0RvcG55LVdnWU85WVY3V3R4NEhLdTE2emxjX1VRWEJjWmxiTW4yZUJMcEhnTGYxd3FVS050emNrUjB2M2s3RnF6THEzQXFTWGI5by1QSXlvcXhkMWR3YTJaMjAxS05qYmw5RG5tMG5oN3g2NE50S1JNWU5qdVZkblk?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOQnhvNWNUS2FIMkIwTHpEUUtGOUZhQzhteVVIakxseDdRS2tHLVZwZTFXWGg1elZiOGdJMUMzeXhiQldLVmh4bFVUWkV5eGh6TXFCMVFGd0RMcW5pdk9aMnBQbEg2c0tTTFhvTWY4Y2l3SDdPbUUwQ2RySEd0X0NzNTREandfSTE2Q05NeEZpYWhQMUlWTlRzamVlelprenVZdURLT3Y1UEprUWtYeFZNa0d2ZHdkWEw0TjNWVjM5djBMYnVBZTFOZzhrOXVaU0Jp?oc=5", "source_name": "Investing.com", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Ideaya Biosciences chief accounting officer sells $382,130 in stock", "summary": "Andres Ruiz Briseno, Chief Accounting Officer of IDEAYA Biosciences, sold 9,550 shares of the company's stock for approximately $382,130. The sale was carried out under a Rule 10b5-1 trading plan and occurred after an exercise of stock options. Despite the sale, the company maint", "url": "https://www.investing.com/news/insider-trading-news/ideaya-biosciences-chief-accounting-officer-sells-382130-in-stock-93CH-4784996", "source_name": "Investing.com", "published_at": "2026-07-10T04:41:21", "published_display": "10 Jul 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Ideaya Biosciences Inc For: 9 July By Investing.com", "summary": "This article reports on a Form 4 filing for Ideaya Biosciences Inc. dated July 9, 2026. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The content provided is minimal, simply stating the company, the form type, and the date.", "url": "https://ng.investing.com/news/stock-market-news/form-4-ideaya-biosciences-inc-for-9-july-93CH-2593972", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T04:39:11", "published_display": "10 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences chief accounting officer sells $382,130 in stock By Investing.com", "summary": "Ideaya Biosciences' Chief Accounting Officer, Andres Ruiz Briseno, sold 9,550 shares totaling $382,130 on July 7, 2026, under a Rule 10b5-1 trading plan. This transaction occurred after he acquired the same number of shares through stock option exercise. Despite the sale occurrin", "url": "https://ng.investing.com/news/stock-market-news/ideaya-biosciences-chief-accounting-officer-sells-382130-in-stock-93CH-2593956", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T22:02:06", "published_display": "09 Jul 2026 22:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences Insider Sold Shares Worth $382,131, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ideaya-biosciences-insider-sold-shares-210147696.html", "source_name": "MT Newswires", "published_at": "2026-07-09T21:01:47+00:00", "published_display": "09 Jul 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares", "summary": "IDEAYA Biosciences' Chief Accounting Officer, Andres Ruiz Briseno, exercised 9,550 stock options at $12.86 per share and subsequently sold all 9,550 common shares at a weighted average price of $40.01 per share. This transaction was pre-planned under a Rule 10b5-1 trading plan ad", "url": "https://www.stocktitan.net/sec-filings/IDYA/form-4-ideaya-biosciences-inc-insider-trading-activity-e43d0f0b0f21.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:10:06", "published_display": "09 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary", "summary": "IDEAYA Biosciences (IDYA) presented a summary of its 43rd Annual J.P. Morgan Healthcare Conference, highlighting multiple first-in-class programs and key clinical milestones. The company is advancing six programs in the clinic and targeting three new INDs for 2025, with significa", "url": "https://quartr.com/events/ideaya-biosciences-idya-43rd-annual-j-p-morgan-healthcare-conference-2025_FkPPo41h", "source_name": "Quartr", "published_at": "2026-07-09T04:39:11", "published_display": "09 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary", "summary": "IDEAYA Biosciences (IDYA) provided an update at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, highlighting the rapid enrollment in its Darovasertib trial for metastatic uveal melanoma, with potential for accelerated approval data readout by late next year. The com", "url": "https://quartr.com/events/ideaya-biosciences-inc-idya-7th-annual-evercore-isi-healthconx-healthcare-conference_FkPPoGuL", "source_name": "Quartr", "published_at": "2026-07-09T04:39:11", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) RBC Capital Markets Global Healthcare Conference 2025 summary", "summary": "IDEAYA Biosciences anticipates a transformational year with four major data readouts for Darovasertib in uveal melanoma, including randomized PFS and OS data by year-end 2025, and plans to launch a registrational neoadjuvant study. The company aims for Accelerated Approval for Da", "url": "https://quartr.com/events/ideaya-biosciences-inc-idya-rbc-capital-markets-global-healthcare-conference-2025_FkPPoZcN", "source_name": "Quartr", "published_at": "2026-07-08T16:40:10", "published_display": "08 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences highlights its precision oncology pipeline as Nasdaq-listed cancer drug developer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQNjhQSnNSVnpQWHVTRVVaQnl4OV8tTTZCVUJ4NG5LeTIzTDBGZEZWeloyWUZEd3d3ZFNTZnhsNWhrVDIwNGlMcEpZal9VLU5ZUS1xcENxanZQZGRnaTFUMEVUTXV6aGhMQ3hHd2EwY3QyUEFMOXhMOUk3M2RNazZWaXZ4cVEtQ0tqM3VFQUUwb2J0VDJBaTJxdkJUei1pVE1PMjF3c01FbEk0Ung4ZHNOSnhpUUZBakJMWFhHdjEyZ3E?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-08T13:40:27+00:00", "published_display": "08 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) Joins Russell Growth Benchmarks, Is The Stock Fully Priced?", "summary": "IDEAYA Biosciences (IDYA) has been included in several Russell Growth Benchmarks, leading to increased investor interest and a 30-day stock return of 43.2%. While the company's Price-to-Sales (P/S) ratio of 17.1x appears high compared to industry averages and its estimated fair P", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/ideaya-biosciences-idya-joins-russell-growth-benchmarks-is-t", "source_name": "Simply Wall Street", "published_at": "2026-07-08T04:11:13", "published_display": "08 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] IDEAYA Biosciences, Inc. SEC Filing", "summary": "This article details an SEC Form 144 filing by IDEAYA Biosciences, Inc. (IDYA) concerning a proposed sale of securities. The document outlines the filer and issuer information, securities to be sold including common stock acquired through stock option exercise, and specifies J.P.", "url": "https://www.stocktitan.net/sec-filings/IDYA/144-ideaya-biosciences-inc-sec-filing-8c8a28ff56c5.html", "source_name": "Stock Titan", "published_at": "2026-07-08T04:09:33", "published_display": "08 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Ideaya Biosciences Inc. (IDYA) Affects Rotational Strategy Timing", "summary": "Ideaya Biosciences Inc. (IDYA) shows strong sentiment across all horizons, leading to an overweight bias. AI models have generated three trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and stop-loss levels. The analysis indica", "url": "https://news.stocktradersdaily.com/news_release/20/How_Ideaya_Biosciences_Inc._IDYA_Affects_Rotational_Strategy_Timing_070826025401_1783493641.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T03:10:36", "published_display": "08 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63", "summary": "Truist Financial has reiterated its Buy rating for IDEAYA Biosciences (IDYA.US) and set a target price of $63. This indicates a positive outlook from the firm regarding the biotechnology company's stock performance.", "url": "https://www.moomoo.com/news/post/72590618/truist-financial-maintains-ideaya-biosciences-idyaus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-07T19:09:33", "published_display": "07 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts IDEAYA Biosciences Price Target to $48 From $53, Maintains Outperform Rating", "summary": "RBC Capital has adjusted its price target for IDEAYA Biosciences to $48, down from $53, while reiterating an \"Outperform\" rating on the stock. This revision reflects a change in valuation despite the maintained positive outlook for the company's performance.", "url": "https://www.moomoo.com/news/post/72585854/rbc-capital-adjusts-ideaya-biosciences-price-target-to-48-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T16:39:38", "published_display": "07 Jul 2026 16:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences stock hits 52-week high at $39.28 By Investing.com", "summary": "Ideaya Biosciences Inc. (NASDAQ: IDYA) has reached a new 52-week high of $39.28, representing an 85.02% increase over the past year and bringing its market capitalization to $3.73 billion. Analysts have set a high price target of $66, reflecting strong investor confidence. The co", "url": "https://za.investing.com/news/stock-market-news/ideaya-biosciences-stock-hits-52week-high-at-3928-93CH-4356737", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T15:40:26", "published_display": "06 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences stock hits 52-week high at $39.28", "summary": "Ideaya Biosciences Inc. stock has reached a 52-week high of $39.28, reflecting an 85.02% increase over the past year and a market capitalization of $3.73 billion. This surge follows a successful public offering raising $345 million and the initiation of a Phase 1 clinical trial f", "url": "https://m.uk.investing.com/news/stock-market-news/ideaya-biosciences-stock-hits-52week-high-at-3928-93CH-4757904?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-06T15:39:27", "published_display": "06 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion", "summary": "IDEAYA Biosciences (IDYA) has been added to several Russell growth and small-cap indexes, increasing its visibility to institutional investors. This inclusion, however, does not alter the core investment risk that depends on successful clinical and regulatory outcomes for its onc", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/how-investors-are-reacting-to-ideaya-biosciences-idya-broad", "source_name": "Simply Wall Street", "published_at": "2026-07-03T14:39:15", "published_display": "03 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "IDEAYA Biosciences announced it granted non-qualified stock options for 98,000 shares to four new employees on June 25, 2026. These grants, made under the 2023 Employment Inducement Incentive Award Plan, are a material inducement for their employment, in compliance with Nasdaq Li", "url": "https://finance.yahoo.com/healthcare/articles/ideaya-biosciences-announces-inducement-grants-100000351.html", "source_name": "Market source", "published_at": "2026-06-30T18:10:29", "published_display": "30 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark", "summary": "IDEAYA Biosciences, Inc. (NasdaqGS:IDYA) has been added to the Russell 2500 Growth Benchmark. The company, an oncology firm focused on developing therapies for cancer, saw its stock price increase by 1.97%. IDEAYA Biosciences engages in the discovery, development, and commerciali", "url": "https://www.marketscreener.com/news/ideaya-biosciences-inc-nasdaqgs-idya-added-to-russell-2500-growth-benchmark-ce7f5fdfdd89f726", "source_name": "marketscreener.com", "published_at": "2026-06-30T13:11:14", "published_display": "30 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. \u2013 FWB:30J", "summary": "This article provides financial information for IDEAYA Biosciences, Inc. (FWB:30J) on TradingView, specifically focusing on its enterprise value to EBIT forward. It lists various general financial and community features available on the platform for this company's stock.", "url": "https://www.tradingview.com/symbols/FWB-30J/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:09:39", "published_display": "30 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark", "summary": "IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), a company focused on oncology therapies, has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion highlights the company's growth trajectory and its position within the small-cap market. The article also provides an o", "url": "https://www.marketscreener.com/news/ideaya-biosciences-inc-nasdaqgs-idya-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f525", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:40:07", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark", "summary": "IDEAYA Biosciences, Inc. (NasdaqGS:IDYA) has been added to the Russell 3000E Growth Benchmark. This news, published on June 29, 2026, highlights the company's inclusion in a significant stock market index. IDEAYA Biosciences is a precision oncology company focused on developing t", "url": "https://www.marketscreener.com/news/ideaya-biosciences-inc-nasdaqgs-idya-added-to-russell-3000e-growth-benchmark-ce7f5fdedc80ff26", "source_name": "marketscreener.com", "published_at": "2026-06-29T13:11:14", "published_display": "29 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of IDEAYA Biosciences, Inc. \u2013 FWB:30J", "summary": "The article provides the \"Price to sales forward\" data for IDEAYA Biosciences, Inc. (FWB:30J) as listed on the Frankfurt Stock Exchange. It indicates that the market is closed and no trades have occurred for this specific financial metric. The data is available through TradingVie", "url": "https://www.tradingview.com/symbols/FWB-30J/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:41:08", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of IDEAYA Biosciences, Inc. \u2013 NASDAQ:IDYA", "summary": "This article provides financial data for IDEAYA Biosciences, Inc. (IDYA) focusing on its price to book forward ratio. It highlights the company's listing on the Nasdaq Stock Market under the Pharmaceuticals: Major category within Health Technology. The content also includes vario", "url": "https://www.tradingview.com/symbols/NASDAQ-IDYA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:41:08", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark", "summary": "IDEAYA Biosciences, Inc. (NasdaqGS: IDYA) has been added to the Russell 2000 Growth Benchmark. The company, which specializes in oncology therapies, recently announced its CEO as Chairman of the Board and initiated a Phase 1/2 clinical study for pancreatic and lung cancers. This ", "url": "https://www.marketscreener.com/news/ideaya-biosciences-inc-nasdaqgs-idya-added-to-russell-2000-growth-benchmark-ce7f5fdede81f02c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:17", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. \u2013 NASDAQ:IDYA", "summary": "This article provides a brief mention of the \"Enterprise value to EBIT forward\" metric for IDEAYA Biosciences, Inc. (NASDAQ: IDYA). It appears to be a stub or a section within a larger financial data platform like TradingView, designed to display key financial ratios for the comp", "url": "https://www.tradingview.com/symbols/NASDAQ-IDYA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:40:17", "published_display": "29 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of IDEAYA Biosciences, Inc. \u2013 NASDAQ:IDYA", "summary": "This article focuses on the enterprise value to revenue forward metric for IDEAYA Biosciences, Inc. (NASDAQ: IDYA). The content presented is a financial data point from TradingView, indicating a key valuation multiple for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-IDYA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:39:07", "published_display": "29 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of IDEAYA Biosciences, Inc. \u2013 FWB:30J", "summary": "The article provides a financial metric for IDEAYA Biosciences, Inc. (FWB:30J), specifically its enterprise value to revenue forward. It notes that this data was \"Made by humans\" and that the market was closed with no trades at the time of publication. The content appears to be a", "url": "https://www.tradingview.com/symbols/FWB-30J/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:40:17", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of IDEAYA Biosciences, Inc. \u2013 FWB:30J", "summary": "This article focuses on the \"Price to book forward\" financial metric for IDEAYA Biosciences, Inc. (FWB:30J) on the Frankfurt Stock Exchange. It indicates no trades and a closed market at the time of publication. The page appears to be a financial data portal displaying an overvie", "url": "https://www.tradingview.com/symbols/FWB-30J/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T22:10:18", "published_display": "28 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) First Patient Enrollment Puts Valuation Back In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNdWdEbmQ1U0gtOHgtWGQ4V2VWVGgxTUVaU1JkbUlBYU5lWnJhQTlqaWhmQW9wclJOREplakxPaFQ0V01sOW9FY1hoblIxWDctV3BYMnJrb3REd1FQRzNtZmd0a01CY2RCajV6dFZYVTkyaDhTd1pOZEtGUDNyYWxSZEZRa1RxaVlkem91SUtDNl9lWkZJYnhvVHd3MWtMdHFyTHMwSWNNNldrNmpEYTI5NldMQ2c1UmVsSVY2M2UydDQyRjRtb3FHWU9JbTlqUG1WaVc2aUFNNHQzMmljMWxibE1nS090Q0HSAewBQVVfeXFMUHBuQnNORkE3UFd2VjAwS0JmZjZ5LVNWWTFySzA0anVDNGxvSDEwSlJvZW9VejJqbmo5aGo2OHR3ZVEtOUttZ0VNSVFYc04xeS1QMEd6MlhjdTU5Uk1HUnIyakgxQ1MzbElRSHdSQXB0VnZuZWRGQzlxNm1uRTFJWk1TZ1pyUk14RTE2NV9Fd2pYcVhNcHVqbXVNRGd0RjhzbnlJSHlvSWpya1Jhc1JaR0VWX1RMa0V0YUxHZ0dXRWJJQW5MeEcyUmVTZU43U1lxZTV6OFFmTDNMRDNXemExN182ZVhCSmxqdEg1dTc?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences Elects CEO Yujiro Hata as Chairman", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ideaya-biosciences-elects-ceo-yujiro-105053830.html", "source_name": "MT Newswires", "published_at": "2026-06-17T10:50:53+00:00", "published_display": "17 Jun 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ideaya-biosciences-announces-yujiro-hata-100000788.html", "source_name": "PR Newswire", "published_at": "2026-06-17T10:00:00+00:00", "published_display": "17 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer research CEO Yujiro Hata now also chairs IDEAYA board", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPcm5DS1VrYnZZeE5RajNxc25nMDBpQV85MTFaOF9LRnJRd0t6OGZpWGFCeFdsQ3BjSnc3RkJFU215ZE9rcloxTktIbi1VaXE0azVGaXFpN0EtNnkzYV9pVHNXZWxkTjE2N1YxOEtlOGw0aVFMb0FSZi1SLTZjM2JxVDVqODlneHBwcDZRNDN0a2dBODMzc3Y0M0t2ZnhFeTBZRnFmVEJFZGRIZnR1SzU4WVRGVDVKWDdKNmlZT1p3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences' Phase 1 Clinical Trial of Lung, Pancreatic Cancer Treatment Enrolls First Patient", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ideaya-biosciences-apos-phase-1-115906264.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:59:06+00:00", "published_display": "15 Jun 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ideaya-biosciences-announces-ide892-potential-100000084.html", "source_name": "PR Newswire", "published_at": "2026-06-15T10:00:00+00:00", "published_display": "15 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ideaya-biosciences-idya-forms-clinical-102033649.html", "source_name": "Insider Monkey", "published_at": "2026-06-11T10:20:33+00:00", "published_display": "11 Jun 2026 10:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion H2 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZnRrTk5RMmEyY2ltNXVDUUVnWkUteXI2M2VqdEdiX2V1LXdhS1k0N3RzOWtLYXVqWXdMMzFoRTZuc1JXc3p3VEpXMm1BLUpBWlcydHZXbG0wY3d4Vjg0OHpXMzd5b2hUNEo4Q2thUjJfa1Q3SnpLaTlwRVFCaTk3ZndCQ2V1dzBjdlpoWVA5b2VsQ2ZmSWt5bTNPd3Q2bmY3TXdUdGZQVDJmTnJzb3NfcE9ybDdXX1paVWJ6T2pWYXRndw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences Closes $345 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ideaya-biosciences-closes-345-million-203152781.html", "source_name": "MT Newswires", "published_at": "2026-06-10T20:31:52+00:00", "published_display": "10 Jun 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (NASDAQ: IDYA) raises $323.6M via stock and pre-funded warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQWWhCSzE0Q3BKN2V3YURmMHQ0aUhLTG1JZU5oc2ZhR2pfTGlDMURydF9pSGthREZKNU14eWVhYlBuQmlNNk1xZU1MU0dldHVSTHJSV3lESXlhdkpuMGRKaWlTbG9FX1JFcnQ4TnRiMXItWVp1QW5scXlvcnQwakVlUXE5X1EyMjBCb0xJa01LVFYtTllNbE9ZbnRyNWNaZHZKZmh2WHNUVXd5eDlxMUxEOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNSUtydXJ1TUhMYlFiS0VEUFYxcWM2X0RLa1ZwUUhJZXNuR0x5TWRCeDlZVHNvMy1BU3VJd083QmZYU2ZCdzZnVU1femRpYXUwY19PeUdRNm9wRkQ5Qm5pZEoyN01fTktrOVREU1g3dEpVX2tqMGhhdHlEXzNGdEpLaDBiSkx3ZWNURnlxd3NnZkVSVHRSc1d6OU9KRWVvdTBwVVVLVVB6clpMRHJqMUs3VzIzZ2ZMdUszYVNKejlYMkpfa3NrS3dlNUJtXy11R1ExbzZtMEVVbnA1ejNDWTluMmI3LVZOWVVwbnVXSjE4NmhyVFZNaWVPN0oweENvOGZPY0JvN1A1NA?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOTGRNUGVqanZiVHpFNkJYWUllOGE2S2lCVFlZNEEtZnA4NzJZS1FHd2ZWOTJ3Z2E3R2VqNWJrTDdXR19UeGx6TVhHaXFieE41SldKWDJsdTV6QzZ3TTFtSnpqdHpJWHdpNHRDX2h2UE52QThSeEMtekE5Y0JJZUI1eGZkVTFpUzdiV1Q5YnV6SUFzWlFXVnN4YjBkc1VpbGFVd19HLWRMUlltXzYzODAtaFNfYV9kdmtmeTVnUDdB?oc=5", "source_name": "BioSpace", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA sets $27 price in $300M stock and warrant sale to investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeU5BaHEwdTc5eE1mZERMQUd0UXlOZDNnNXZPZHcwdVdySXlPRmUyTmNkSUx2YUJlTXBOLV9fWnZHd2FGY1NuaDNEeWxvamQ1VlFIMkdkY2Z2bWExZ2NjZDJKOENKd1haams2N0JYSS14TUcycEhzQjN4YTVYNUp2Zkdvd3NJMFE2Vzl1QW5fRHMyM1lSZHdoVWlOR2tySjByYzVmbDV4TW1LU1V3R1JKc0tlQjNFeW1hX21EWU5RWlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech IDEAYA grants new hires 221,000 options over 4 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOY2Vhb1pFcWtIMTRsa1FQLTBMb1I2Tk1kSWtZY0Q1YkV2LVV2bHRoNTgyc1hSZEcwZmNtVUJNQWRvR0laSEJwZDhsdWxiRVI3Ql9mLS0xUDJYRjU4cDVDN3NnLS0tRzlJbnRReHNQNUJ4aXdVVlZqRkRRR1U2VGtTazhHOEZGQ1hVVmE3SGtuMkNQR3Y5ZjQ2MG4tN1dYOG9SOVZmT3VPN1RzdjJnMzZXRnVLQktsa1RFUWhXMHVvcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA Biosciences (IDYA) Persistent Losses Challenge Bullish High Revenue Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQdEhSYV9uUndPVmx1UVVaZ2k2b3ZrU28xemhMMXVyRDZZWlZ0U0IteGFEUElEazE0NXJPVDVJZlBHc01EdjZRS09zVjFXWnd3eGpGZk90ZXhGN2E3R0Jub01mSUtjT1N4cG00eUthYWtCYU1UMGRWVW9vLW56YnM4VW9Va2d2ZVNwZi1mdkZNQ29WdHNhWm92WGFsaXhlQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five new IDEAYA hires receive stock options at $29.10 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMzlrVnpnbld1bFJmNkFxY202LWppWTdBQktONW1VT09NZ1U4ZEFIS1VScjIwMHM2eWs4aXdRRldQZzhUdnktVEVuVERnSlJ0Vk1VM3Rfa1ZLOG14ZzRadVkyR215aFpkd0pSNWtnd0xfVmZXc2NqRlZKX01EMFdrMGg5Zjl4WFBmLWp1bGtDWnFUZTMtdUtIRU1nOS1ETzZ5d3dvb2M5RVhPZ2RPSk1rTVFWMnZrZHk0cnVlMEQ5aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences: Stock Buoyant On Good mUM Data - But Approval Not A Formality", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQRlYyTlZ0UUZvc1NrRUtIaG9xa0NQcEZjV00wZnBMWmU0QmtnZnlfd0xSeE9TZG5NUEZaSjhrS2MzQ0RCX0RhQ3AtQW5iTjhUMGtoSlNTcVYxT1JvemJiUUpFYjUzdXA3YnRmbld1ZHpMSG05X3ByYlFnQVctNm5yNUxoeXBJb0hza0xCcHNpcFpRSDV3X1JjY08xTS12X1hLTHl0NzVDbjBNQ3F2dHJwRlBDdVlWRGJtQWYw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQQ0d1eWtNUzI2MGV4amx0NkN0c0VGNjBWWURDRVM3dTJ5WS1kZjNqaUhyMXhqeFdQb2JfZFVoaXFFSEM4ZnZCQW16SnFFN0RwT1J0R2JNdG5sUEp2RFB1NlFGZDZUR3hudXA2emNTUVFJYlJsS1NycUhaQWVlX0FONmowZUV6Znd6TVBtN2t6Yk1ycndSUVNycUlkWVY2cnQ4?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IDEAYA to reveal April 13 trial data in metastatic uveal melanoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxObGlRY1U2ckpQcGcyeXk5dVJGamhmS1ZEZWpMbXlvZkxWaFRVN0VienhqRXo1bGwyZHlmSHhOYmo2LTFLZTlXMzFSR2RWMUMza3FYX0h1dzdYNEw1M2hBSHF6akxsaDRlV0FYTk5hdjQtTWlXczhCdmxrNVRsamtjei1zazZOeTF3ZjQ5TEFCOEtycWZjUmp6RmlnS2s0NWtKZl9Ca0pETjEzT0xabFgta1RvRzFiYWFHdnc0QjV1WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQVjFwSldqWFJ6R1JFbFdXZy1XZjZVNmNSU1JKaVRCcGswcUVWdGdiUktRd0RvcG55LVdnWU85WVY3V3R4NEhLdTE2emxjX1VRWEJjWmxiTW4yZUJMcEhnTGYxd3FVS050emNrUjB2M2s3RnF6THEzQXFTWGI5by1QSXlvcXhkMWR3YTJaMjAxS05qYmw5RG5tMG5oN3g2NE50S1JNWU5qdVZkblk?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOQnhvNWNUS2FIMkIwTHpEUUtGOUZhQzhteVVIakxseDdRS2tHLVZwZTFXWGg1elZiOGdJMUMzeXhiQldLVmh4bFVUWkV5eGh6TXFCMVFGd0RMcW5pdk9aMnBQbEg2c0tTTFhvTWY4Y2l3SDdPbUUwQ2RySEd0X0NzNTREandfSTE2Q05NeEZpYWhQMUlWTlRzamVlelprenVZdURLT3Y1UEprUWtYeFZNa0d2ZHdkWEw0TjNWVjM5djBMYnVBZTFOZzhrOXVaU0Jp?oc=5", "source_name": "Investing.com", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 64, "sentiment_summary": {"positive": 17, "negative": 2, "neutral": 45, "score": 57, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 22.9, "count": 41}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.55, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 36.99, "latest_week": "2026-07-10", "one_week_move": -1.8, "four_week_move": 27.6, "twelve_week_move": 9.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.799047, "market_dynamics_buy_signal": false, "relative_strength": 4.002732, "fair_value_gap": 21.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.1901, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.8% over one week, +27.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "simplywall.st", "count": 5}, {"label": "MT Newswires", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Quartr", "count": 3}, {"label": "PR Newswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 41}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 4}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.8% over one week, +27.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Ideaya Biosciences chief accounting officer sells $382,130 in stock"}], "updated_at": "2026-07-16T02:08:14.953228+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}